دورية أكاديمية
أعرض في EDS

Acceptability of HPV vaccination for cervical cancer prevention amongst emerging adult women in rural Mysore, India: a mixed-methods study.

التفاصيل البيبلوغرافية
العنوان: Acceptability of HPV vaccination for cervical cancer prevention amongst emerging adult women in rural Mysore, India: a mixed-methods study.
المؤلفون: Coursey K; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA. Kcoursey@mednet.ucla.edu., Muralidhar K; Public Health Research Institute of India, Mysore, Karnataka, 570020, India.; JSS Academy of Higher Education and Research, Mysuru, Karnataka, 570004, India., Srinivas V; Public Health Research Institute of India, Mysore, Karnataka, 570020, India., Jaykrishna P; Public Health Research Institute of India, Mysore, Karnataka, 570020, India., Begum F; Public Health Research Institute of India, Mysore, Karnataka, 570020, India., Ningaiah N; Public Health Research Institute of India, Mysore, Karnataka, 570020, India., Lee SJ; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA., Madhivanan P; Public Health Research Institute of India, Mysore, Karnataka, 570020, India.; Department of Health Promotion Sciences, Zuckerman College of Public Health, University of Arizona, Mel & Enid, Tucson, AZ, 85724, USA.
المصدر: BMC public health [BMC Public Health] 2024 Aug 07; Vol. 24 (1), pp. 2139. Date of Electronic Publication: 2024 Aug 07.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100968562 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2458 (Electronic) Linking ISSN: 14712458 NLM ISO Abbreviation: BMC Public Health Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: Papillomavirus Vaccines*/administration & dosage , Uterine Cervical Neoplasms*/prevention & control , Papillomavirus Infections*/prevention & control , Focus Groups* , Rural Population*/statistics & numerical data , Patient Acceptance of Health Care*/statistics & numerical data , Patient Acceptance of Health Care*/psychology, Humans ; Female ; India ; Adult ; Young Adult ; Adolescent ; Qualitative Research ; Health Knowledge, Attitudes, Practice
مستخلص: Background: India has the highest number of estimated deaths from cervical cancer globally, with most cases attributed to Human papillomavirus (HPV). The World Health Organization recommends primary HPV vaccination for girls ages 9-14, with catch-up vaccination for young women ≥ 15 if feasible. India authorized a new, inexpensive HPV vaccine in 2022; given anticipated vaccine expansion, we conducted a mixed-methods study exploring acceptability of HPV catch-up vaccination for young emerging adult women in rural Mysore, India.
Methods: Between September 2022-April 2023, participants were recruited with assistance from community health workers. In the qualitative phase, gender-stratified, audio-recorded focus group discussions (FGDs) were conducted in Kannada with emerging adults ages 18-26. FGDs were transcribed, translated, and analyzed using rapid approach to identify key HPV vaccination attributes. In the quantitative phase, a conjoint analysis was conducted to assess the impact of seven vaccination attributes on likelihood to vaccinate (LTV). Women ages 18-26 ranked LTV in eight hypothetical vaccination scenarios, and the relative impact of each attribute on LTV was calculated. All participants received education about cervical cancer, HPV, and HPV vaccination.
Results: Fifty-two young adults (female = 31, male = 21) participated in seven FGDs, and 101 women participated in the conjoint analysis. Average age of the 153 participants was 22.5 years, 66.7% had married, and all had completed high school. Only 17.9% had heard of cervical cancer, and 2.7% knew of the HPV vaccine. FGDs identified seven HPV vaccination attributes: cost, vaccination location, family support, peer influence, dose number, side effects, and risk of acquiring HPV. In the conjoint analysis, all attributes except dose number significantly impacted LTV. Family support (impact score = 19.37, p < 0.0001) and peer influence (impact score = 18.01, p < 0.0001) had the greatest influence, followed by cost (impact score = 16.64, p < 0.0001) and HPV risk (impact score = 12.31, p < 0.0001). Vaccination location (government centers preferred) and side effects were also significant.
Conclusion: Participants had poor knowledge of cervical cancer and HPV. Social attributes (family support, peer influence) had greatest impacts on LTV, and future studies should explore family-based interventions and peer education. Providing free vaccines at government centers through India's national immunization program would maximize catch-up HPV vaccination for rural young women.
(© 2024. The Author(s).)
References: PLoS One. 2016 Nov 18;11(11):e0166713. (PMID: 27861611)
AIDS Care. 2013;25(12):1592-8. (PMID: 23651439)
Cancer Epidemiol. 2014 Dec;38(6):748-56. (PMID: 25305098)
J Cancer Educ. 2020 Feb;35(1):61-68. (PMID: 30460493)
Lancet Oncol. 2019 Nov;20(11):e637-e644. (PMID: 31674322)
Cancer Med. 2019 Oct;8(14):6195-6211. (PMID: 31305011)
Int J STD AIDS. 2011 May;22(5):256-62. (PMID: 21571973)
Hum Vaccin Immunother. 2021 Apr 3;17(4):1211-1222. (PMID: 32966146)
J Glob Health. 2022 Nov 29;12:05052. (PMID: 36579668)
Ann Glob Health. 2020 Mar 16;86(1):30. (PMID: 32211300)
Vaccine. 2006 Mar 15;24(12):2094-101. (PMID: 16332402)
Health Econ. 1998 Jun;7(4):373-8. (PMID: 9683097)
Asian Pac J Cancer Prev. 2021 Mar 01;22(3):699-704. (PMID: 33773531)
BMC Public Health. 2022 Apr 13;22(1):743. (PMID: 35418068)
Value Health. 2011 Jun;14(4):403-13. (PMID: 21669364)
Hum Vaccin Immunother. 2022 Nov 30;18(6):2122494. (PMID: 36130214)
Indian J Med Res. 2022 Aug;156(2):319-329. (PMID: 36629192)
J Family Med Prim Care. 2020 Jul 30;9(7):3343-3348. (PMID: 33102294)
Lancet Oncol. 2023 Apr;24(4):e147. (PMID: 36934729)
Vaccine. 2017 Oct 13;35(43):5753-5755. (PMID: 28596091)
South Asian J Cancer. 2023 Feb 25;12(1):9-16. (PMID: 36851931)
Vaccine. 2022 Mar 31;40 Suppl 1:A17-A25. (PMID: 34429233)
J Cancer Educ. 2021 Aug;36(4):844-849. (PMID: 32112367)
Cancer Sci. 2013 Apr;104(4):465-72. (PMID: 23331518)
Lancet Oncol. 2022 Nov;23(11):1419-1429. (PMID: 36174583)
J Infect Dis. 2015 Jan 15;211(2):172-4. (PMID: 25057043)
Indian J Med Res. 2022 Oct-Nov;156(4&5):598-607. (PMID: 36510887)
PLOS Glob Public Health. 2022 Dec 6;2(12):e0001321. (PMID: 36962889)
Asian Pac J Cancer Prev. 2015;16(12):4895-900. (PMID: 26163611)
Elife. 2023 Apr 18;12:. (PMID: 37070731)
South Asian J Cancer. 2023 Feb 25;12(1):1-8. (PMID: 36851937)
Am J Trop Med Hyg. 2021 Aug 09;105(4):966-973. (PMID: 34370698)
J Educ Health Promot. 2019 Nov 29;8:216. (PMID: 31867380)
Vaccine X. 2022 Oct 15;12:100228. (PMID: 36317080)
J Immigr Minor Health. 2023 Dec;25(6):1307-1314. (PMID: 37071376)
Lancet Oncol. 2018 Feb;19(2):e84. (PMID: 29413482)
BMC Public Health. 2022 Aug 24;22(1):1611. (PMID: 36002832)
Health Promot Pract. 2022 Nov;23(6):1039-1049. (PMID: 34636268)
Vaccine. 2019 Feb 21;37(9):1174-1181. (PMID: 30709724)
J Cancer Educ. 2015 Mar;30(1):130-7. (PMID: 25355525)
Asian Pac J Cancer Prev. 2015;16(12):5053-8. (PMID: 26163640)
Lancet Oncol. 2013 Nov;14(12):e492. (PMID: 24176568)
Indian J Med Res. 2022 Jan;156(1):94-103. (PMID: 36510902)
Psychol Sci Public Interest. 2017 Dec;18(3):149-207. (PMID: 29611455)
Hum Resour Health. 2019 Oct 22;17(1):73. (PMID: 31640722)
MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698-702. (PMID: 31415491)
Dialogues Health. 2022 Dec;1:100044. (PMID: 36785639)
BMC Public Health. 2023 Apr 11;23(1):671. (PMID: 37041530)
Acad Pediatr. 2021 May-Jun;21(4S):S9-S16. (PMID: 33958099)
J Family Med Prim Care. 2023 Jan;12(1):189-190. (PMID: 37025231)
AIDS Behav. 2020 Apr;24(4):1226-1236. (PMID: 31655915)
J Cancer Educ. 2017 Jun;32(2):382-391. (PMID: 26880357)
Public Health Pract (Oxf). 2022 Dec;4:100300. (PMID: 35874794)
Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Oct 6;56(10):1494-1498. (PMID: 36274620)
AIDS Care. 2008 Nov;20(10):1161-8. (PMID: 18608068)
Asian Pac J Cancer Prev. 2016;17(8):3663-73. (PMID: 27644600)
J Obstet Gynaecol India. 2023 Apr;73(2):113-122. (PMID: 37073237)
Indian J Public Health. 2022 Apr-Jun;66(2):104-108. (PMID: 35859489)
Int J Adolesc Med Health. 2020 May 01;34(1):. (PMID: 32352403)
معلومات مُعتمدة: P30 MH058107 United States MH NIMH NIH HHS
فهرسة مساهمة: Keywords: Cervical cancer; Conjoint analysis; HPV; India; Vaccination; Vaccine acceptability
المشرفين على المادة: 0 (Papillomavirus Vaccines)
تواريخ الأحداث: Date Created: 20240807 Date Completed: 20240808 Latest Revision: 20240904
رمز التحديث: 20240904
مُعرف محوري في PubMed: PMC11304586
DOI: 10.1186/s12889-024-19485-8
PMID: 39112938
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-2458
DOI:10.1186/s12889-024-19485-8